Page last updated: 2024-12-10

budlein a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

budlein A: anti-inflammatory and analgesic sesquiterpene lactone from Viguiera robusta; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Viguieragenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID5281430
CHEMBL ID1173297
CHEBI ID3208
MeSH IDM0510402

Synonyms (10)

Synonym
59481-48-0
budlein a
CHEMBL1173297 ,
chebi:3208 ,
2-butenoic acid, 2-methyl-, 2,3,3a,4,5,6,7,11-octahydro-10-(hydroxymethyl)-6-methyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca(b)furan-4-yl ester, (3ar-(3ar*,4r*(z),6r*,10z,11ar))-
Q27105993
[(2z,4r,8r,9r,11r)-2-(hydroxymethyl)-11-methyl-7-methylidene-6,12-dioxo-5,14-dioxatricyclo[9.2.1.04,8]tetradeca-1(13),2-dien-9-yl] (z)-2-methylbut-2-enoate
bdbm50466117
2-butenoic acid, 2-methyl-, (3ar,4r,6r,10z,11ar)-2,3,3a,4,5,6,7,11a-octahydro-10-(hydroxymethyl)-6-methyl-3-methylene-2,7-dioxo-6,9-epoxycyclodeca[b]furan-4-yl ester, (2z)-
DTXSID201099066

Research Excerpts

Overview

Budlein A is a sesquiterpene lactone found in high amounts in American sunflower-like species of the genus Viguiera (Asteraceae) It has anti-inflammatory properties related to the inhibition of pro-inflammatory cytokines and neutrophil recruitment.

ExcerptReferenceRelevance
"Budlein A is a sesquiterpene lactone with antinociceptive and anti-inflammatory properties related to the inhibition of pro-inflammatory cytokines and neutrophil recruitment."( The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines.
Arakawa, NS; Casagrande, R; Cunha, FQ; Cunha, TM; da Costa, FB; Fattori, V; Pinho-Ribeiro, FA; Pinto, LG; Ruiz-Miyazawa, KW; Souto, FO; Turato, WM; Verri, WA; Zarpelon, AC, 2017
)
1.47
"Budlein A is a sesquiterpene lactone found in high amounts in American sunflower-like species of the genus Viguiera (Asteraceae)."( Unusual biotransformation products of the sesquiterpene lactone budlein A by Aspergillus species.
Ambrosio, SR; Antonucci, GA; Arakawa, NS; Da Costa, FB; Gobbo-Neto, L; Pupo, MT; Said, S; Sampaio, SV; Schmidt, TJ, 2013
)
1.35
"Budlein A is a sesquiterpene lactone (STL) with some reported biological activities. "( A systematic investigation of the fragmentation pattern of two furanoheliangolide C-8 stereoisomers using electrospray ionization mass spectrometry.
Da Costa, FB; Humpf, HU; Lopes, NP; Sartori, LR; Vessecchi, R, 2014
)
1.85
"Budlein A is a SL isolated from the species Aldama buddlejiformis and A."( Effects of budlein A on human neutrophils and lymphocytes.
Amôr, NG; Arakawa, NS; Campanelli, AP; Costa, FB; Gasparoto, TH; Knob, CD; Oliveira, CE; Silva, M,
)
1.24
"Budlein A is a potent inhibitor of LPS-induced leukocyte accumulation in vivo."( Budlein A from Viguiera robusta inhibits leukocyte-endothelial cell interactions, adhesion molecule expression and inflammatory mediators release.
Arakawa, NS; Da Costa, FB; Faccioli, LH; Jose, PJ; Nicolete, R; Nomizo, A; Rius, C; Sanz, MJ, 2009
)
2.52

Effects

ExcerptReferenceRelevance
"Budlein A has been reported to exert some analgesic and anti-inflammatory properties. "( Budlein A from Viguiera robusta inhibits leukocyte-endothelial cell interactions, adhesion molecule expression and inflammatory mediators release.
Arakawa, NS; Da Costa, FB; Faccioli, LH; Jose, PJ; Nicolete, R; Nomizo, A; Rius, C; Sanz, MJ, 2009
)
3.24

Treatment

The treatment with budlein A dose--(1.0-10.0 mg/kg, p.o.) dependently inhibited the carrageenan-induced: i. . Budlein A treatment dose-dependently inhibited AIA-induced mechanical hyperalgesia, edema, total leukocytes and neutrophil recruitment, and proteoglycan degradation.

ExcerptReferenceRelevance
"Budlein A treatment dose-dependently inhibited AIA-induced mechanical hyperalgesia, edema, total leukocytes and neutrophil recruitment, and proteoglycan degradation."( The Sesquiterpene Lactone, Budlein A, Inhibits Antigen-Induced Arthritis in Mice: Role of NF-κB and Cytokines.
Arakawa, NS; Casagrande, R; Cunha, FQ; Cunha, TM; da Costa, FB; Fattori, V; Pinho-Ribeiro, FA; Pinto, LG; Ruiz-Miyazawa, KW; Souto, FO; Turato, WM; Verri, WA; Zarpelon, AC, 2017
)
1.47
"The treatment with budlein A dose--(1.0-10.0 mg/kg, p.o., respectively) dependently inhibited the carrageenan-induced: i."( Anti-inflammatory and analgesic effects of the sesquiterpene lactone budlein A in mice: inhibition of cytokine production-dependent mechanism.
Arakawa, NS; Cunha, FQ; Cunha, TM; Da Costa, FB; Ferreira, SH; Lemos, HP; Parada, CA; Valério, DA; Verri, WA, 2007
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1417116Antileishmanial activity against Leishmania donovani amastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417102Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID492425Antimalarial activity against Plasmodium falciparum2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Antimalarials from nature.
AID1417117Antitrypanosomal activity against Trypanosoma cruzi amastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417094Inhibition of recombinant oligo-histidine-tagged Leishmania major DHODH expressed in Escherichia coli BL21(DE3) cells using DHO as substrate measured after 60 secs2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1417118Antileishmanial activity against Leishmania infantum MHOM/BR/1972/LD promastigotes2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's5 (55.56)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]